KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbbVie (ABBV) EBIT Margin (2016 - 2025)

AbbVie (ABBV) has disclosed EBIT Margin for 14 consecutive years, with 27.34% as the latest value for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 3721.0% to 27.34% in Q4 2025 year-over-year; TTM through Dec 2025 was 24.65%, a 843.0% increase, with the full-year FY2025 number at 24.65%, up 843.0% from a year prior.
  • EBIT Margin was 27.34% for Q4 2025 at AbbVie, up from 12.07% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 36.39% in Q4 2022 to a low of 9.87% in Q4 2024.
  • A 5-year average of 25.62% and a median of 27.81% in 2024 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: plummeted -3221bps in 2024, then skyrocketed 3721bps in 2025.
  • AbbVie's EBIT Margin stood at 34.09% in 2021, then rose by 7bps to 36.39% in 2022, then crashed by -39bps to 22.34% in 2023, then plummeted by -144bps to 9.87% in 2024, then soared by 377bps to 27.34% in 2025.
  • Per Business Quant, the three most recent readings for ABBV's EBIT Margin are 27.34% (Q4 2025), 12.07% (Q3 2025), and 31.73% (Q2 2025).